The impact of obesity on stem cell transplant

Energy Balance and Hematologic Malignancies

Volumn , Issue , 2012, Pages 129-140

  Navarro, Willis H ^a   Loberiza, Fausto R ^b  

^a NATIONAL MARROW DONOR PROGRAM   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883743165     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-2403-1_6     Document Type: Chapter

References (30)

1. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71-87
2. Jain R, Chung SM, Jain L, Khurana M, Lau SW, Lee JE, et al (2011) Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 90(1):77-89
3. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH (2009) The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 9:88
4. Flegal KM, Graubard BI, Williamson DF, Gail MH (2007) Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 298(17):2028-37
5. WHO (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization technical report series, vol 894. WHO, Geneva, pp i-xii, 1-253
6. Kosti RI, Panagiotakos DB (2006) The epidemic of obesity in children and adolescents in the world. Cent Eur J Public Health 14(4):151-9
7. Low S, Chin MC, Deurenberg-Yap M (2009) Review on epidemic of obesity. Ann Acad Med 38(1):57-9
8. Misra A, Khurana L (2008) Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 93(11 Suppl 1):S9-30
9. Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6(8):1321-7
10. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM (1989) Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 25(2):139-42
11. Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, et al (2007) Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25(30):4707-13
12. Grigg A, Harun MH, Szer J (1997) Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey. Leuk Lymphoma 25(5-6):487-91
13. Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD, et al (2001) Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 27(11):1121-4
14. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al (1996) Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17(2):225-30
15. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, et al (1989) Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25(1):55-61
16. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, et al (1997) Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89(8):3055-60
17. Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR, et al (1999) The impact of obesity and disease on busulfan oral clearance in adults. Blood 93(12):4436-40
18. Nguyen L, Leger F, Lennon S, Puozzo C (2006) Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 57(2):191-8
19. De Jonge ME, Mathot RA, Van Dam SM, Beijnen JH, Rodenhuis S (2002) Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother Pharmacol 50(3):251-5
20. Meloni G, Proia A, Capria S, Romano A, Trape G, Trisolini SM, et al (2001) Obesity and autologous stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplant 28(4):365-7
21. Tarella C, Caracciolo D, Gavarotti P, Argentino C, Zallio F, Corradini P, et al (2000) Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft. Bone Marrow Transplant 26(11):1185-91
22. Dickson TM, Kusnierz-Glaz CR, Blume KG, Negrin RS, Hu WW, Shizuru JA, et al (1999) Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biol Blood Marrow Transplant 5(5):299-305
23. Deeg HJ, Seidel K, Bruemmer B, Pepe MS, Appelbaum FR (1995) Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant 15(3):461-8
24. Vogl DT, Wang T, Perez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, et al (2011) Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 17(12):1765-74
25. Navarro WH, Loberiza FR Jr, Bajorunaite R, van Besien K, Vose JM, Lazarus HM, et al (2006) Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 12(5):541-51
26. Navarro WH, Agovi MA, Logan BR, Ballen K, Bolwell BJ, Frangoul H, et al (2010) Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) in adults. Biol Blood Marrow Transplant 16(10):1442-50
27. Pine M, Wang L, Harrell FE Jr, Calder C, Manes B, Evans M, et al (2010) The effect of obesity on outcome of unrelated cord blood transplant in children with malignant diseases. Bone Marrow Transplant 46(10):1309-13
28. Barker CC, Agovi MA, Logan B, Lazarus HM, Ballen KK, Gupta V, et al (2011) Childhood obesity and outcomes after bone marrow transplantation for patients with severe aplastic anemia. Biol Blood Marrow Transplant 17(5):737-44
29. Fleming DR, Rayens MK, Garrison J (1997) Impact of obesity on allogeneic stem cell transplant patients: a matched case-controlled study. Am J Med 102(3):265-8
30. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, et al (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. New Engl J Med 338(14):962-8